13D Filings
ESSA Pharma Inc.
Initial Filing
Ownership

9.50%

Total Shares

4,221,546

Issuer CIK

1633932

CUSIP

29668H708

Event Date

Apr 23, 2025

Accepted

Apr 24, 2025, 08:56 AM

Reporting Persons (1)
NameType% of ClassAggregateSole VotingShared Voting
BML Investment Partners, L.P.
Partnership
9.50%4,221,54604,221,546
Disclosure Items (7)

Security Title

Common Shares

Issuer Name

ESSA Pharma Inc.

Issuer Address

Suite 720, 999 West Broadway, Vancouver, British Columbia,, Z4, V5Z 1K5

Filing Persons

Braden M. Leonard Mr. Leonard's business address is 65 E Cedar Suite 2, Zionsville, IN 46077. Mr. Leonard's principal business is to serve as managing member of BML Capital Management, LLC.

Business Address

65 E Cedar - Suite 2, Zionsville IN 46077

Principal Occupation

See above.

Convictions

During the past five years, none of BML Investment Partners, L.P., BML Capital Management, LLC or Braden M. Leonard have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or a party to a civil proceeding of a judicial or administrative body of competent jurisdiction where as a result of such proceeding BML Investment Partners, L.P., BML Capital Management, LLC or Braden M. Leonard was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Citizenship

Braden M. Leonard is a citizen of the United States of America.

BML Investment Partners, L.P. holds 4,221,546 shares of Common Stock which were acquired using $6,476,584 of working capital.

The Reporting Persons purchased the Common Stock reported hereunder for investment purposes, and such purchases were made in the Reporting Persons' ordinary course of business. As with their other investments, the Reporting Persons continuously evaluate the Issuer, including but not limited to its businesses, results of operations, and prospects. All of the shares of Common Stock reported herein as being beneficially owned by the Reporting Persons were acquired for investment purposes. Except as set forth herein, none of the Reporting Persons has any plans or proposals that related to or would result in any of the transactions described in Item 4 of Schedule 13D. On April 24, 2025, the Reporting Person sent a letter to the Issuer's Board expressing its belief that an orderly winddown, liquidation, and capital return is in the best interets of the shareholders of the Issuer. The Reporting Persons reserve the right to acquire, or cause to be acquired, additional securities of the Issuer, to dispose of, or cause to be disposed, such securities at any time or to formulate other purposes, plans or proposals regarding the Issuer or any of its securities, to the extent deemed advisable in light of general investment and trading policies of the Reporting Persons, market conditions or other factors.

Percentage of Class

BML Investment Partners, L.P. beneficially owned 4,221,546 shares of the Issuer's Common Stock, or 9.5%.

Number of Shares

4,221,546

Transactions

None of the Reporting Persons has effected any transactions in the Issuer's Common Stock during the 60 days preceding the date of this Schedule 13D.

Shareholders

Braden M Leonard is the Managing Member of BML Capital Management, LLC, which is the General Partner to BML Investment Partners, L.P.

Date of 5% Ownership

N/A

To the best of the knowledge of the Reporting Persons, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Persons or between the Reporting Persons and any person with respect to any securities of the Issuer, including but not limited to transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

1 - Letter dated April 24, 2025 from BML Capital Management, LLC to the Board of Directors of the Issuer.

ESSA Pharma Inc. — Schedule 13D | 13D Filings